Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

      Keywords

      Abbreviations:

      ASE (American Society of Echocardiography), BNP (Brain-type natriuretic peptide), CAD (Coronary artery disease), CMR (Cardiac magnetic resonance), CTRCD (Cancer therapeutics–related cardiac dysfunction), DTI (Doppler tissue imaging), EACVI (European Association of Cardiovascular Imaging), EAE (European Association of Echocardiography), GLS (Global longitudinal strain), HF (Heart failure), LGE (Late gadolinium enhancement), LV (Left ventricular), LVEF (Left ventricular ejection fraction), MUGA (Multigated blood pool imaging), NT-proBNP (N-terminal pro–B-type natriuretic peptide), RV (Right ventricular), STE (Speckle-tracking echocardiography), 3D (Three-dimensional), 3DE (Three-dimensional echocardiography), TnI (Troponin I), 2D (Two-dimensional), 2DE (Two-dimensional echocardiography), VEGF (Vascular endothelial growth factor)
      To read this article in full you will need to make a payment
      ASE Member Login
      ASE Members, full text access to the journal is a member benefit. Login with your ASE credentials to read JASE content.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tan C.
        • Tasaka H.
        • Yu K.P.
        • Murphy M.L.
        • Karnofsky D.A.
        Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia.
        Cancer. 1967; 20: 333-353
        • Alexander J.
        • Dainiak N.
        • Berger H.J.
        • Goldman L.
        • Johnstone D.
        • Reduto L.
        • et al.
        Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
        N Engl J Med. 1979; 300: 278-283
        • Lenzhofer R.
        • Dudczak R.
        • Gumhold G.
        • Graninger W.
        • Moser K.
        • Spitzy K.H.
        Noninvasive methods for the early detection of doxorubicin-induced cardiomyopathy.
        J Cancer Res Clin Oncol. 1983; 106: 136-142
        • Ramos A.
        • Meyer R.A.
        • Korfhagen J.
        • Wong K.Y.
        • Kaplan S.
        Echocardiographic evaluation of adriamycin cardiotoxicity in children.
        Cancer Treat Rep. 1976; 60: 1281-1284
        • Ewer M.S.
        • Ali M.K.
        • Mackay B.
        • Wallace S.
        • Valdivieso M.
        • Legha S.S.
        • et al.
        A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.
        J Clin Oncol. 1984; 2: 112-117
        • Neilan T.G.
        • Jassal D.S.
        • Perez-Sanz T.M.
        • Raher M.J.
        • Pradhan A.D.
        • Buys E.S.
        • et al.
        Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury.
        Eur Heart J. 2006; 27: 1868-1875
        • Khouri M.G.
        • Douglas P.S.
        • Mackey J.R.
        • Martin M.
        • Scott J.M.
        • Scherrer-Crosbie M.
        • et al.
        Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.
        Circulation. 2012; 126: 2749-2763
        • Zhang S.
        • Liu X.
        • Bawa-Khalfe T.
        • Lu L.S.
        • Lyu Y.L.
        • Liu L.F.
        • et al.
        Identification of the molecular basis of doxorubicin-induced cardiotoxicity.
        Nat Med. 2012; 18: 1639-1642
        • Friedman M.A.
        • Bozdech M.J.
        • Billingham M.E.
        • Rider A.K.
        Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals.
        JAMA. 1978; 240: 1603-1606
        • Ewer M.S.
        • Lippman S.M.
        Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
        J Clin Oncol. 2005; 23: 2900-2902
        • Felker G.M.
        • Thompson R.E.
        • Hare J.M.
        • Hruban R.H.
        • Clemetson D.E.
        • Howard D.L.
        • et al.
        Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.
        N Engl J Med. 2000; 342: 1077-1084
        • Lal H.
        • Kolaja K.L.
        • Force T.
        Cancer genetics and the cardiotoxicity of the therapeutics.
        J Am Coll Cardiol. 2013; 61: 267-274
        • Ewer M.
        • Suter D.
        • Lenihan D.J.
        • Niculescu L.
        • Breazna A.
        • Motzer R.J.
        • et al.
        Sunitinib-related hypertension is a randomized placebo-controlled trial of GIST patients.
        J Clin Oncol. 2010; 28 (abstract 10059-abstract 10059)
        • Ewer M.S.
        • Perez E.A.
        • Baselga J.
        • Bell R.
        • Brutsaert D.
        • Marty M.
        • et al.
        P176 Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer.
        The Breast. 2007; 16: S63
        • Daher I.N.
        • Kim C.
        • Saleh R.R.
        • Plana J.C.
        • Yusuf S.W.
        • Banchs J.
        Prevalence of abnormal echocardiographic findings in cancer patients: a retrospective evaluation of echocardiography for identifying cardiac abnormalities in cancer patients.
        Echocardiography. 2011; 28: 1061-1067
        • Cheitlin M.D.
        • Armstrong W.F.
        • Aurigemma G.P.
        • Beller G.A.
        • Bierman F.Z.
        • Davis J.L.
        • et al.
        ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography).
        J Am Soc Echocardiogr. 2003; 16: 1091-1110
        • American College of Cardiology Foundation Appropriate Use Criteria Task Force
        • American Society of Echocardiography
        • American Heart Association
        • American Society of Nuclear Cardiology
        • Heart Failure Society of America
        • Heart Rhythm Society
        • et al.
        ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians.
        J Am Soc Echocardiogr. 2011; 24: 229-267
        • Steingart R.M.
        • Bakris G.L.
        • Chen H.X.
        • Chen M.H.
        • Force T.
        • Ivy S.P.
        • et al.
        Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
        Am Heart J. 2012; 163: 156-163
        • Eschenhagen T.
        • Force T.
        • Ewer M.S.
        • de Keulenaer G.W.
        • Suter T.M.
        • Anker S.D.
        • et al.
        Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
        Eur J Heart Fail. 2011; 13: 1-10
        • Lang R.M.
        • Bierig M.
        • Devereux R.B.
        • Flachskampf F.A.
        • Foster E.
        • Pellikka P.A.
        • et al.
        Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.
        J Am Soc Echocardiogr. 2005; 18: 1440-1463
        • Isner J.M.
        • Ferrans V.J.
        • Cohen S.R.
        • Witkind B.G.
        • Virmani R.
        • Gottdiener J.S.
        • et al.
        Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy.
        Am J Cardiol. 1983; 51: 1167-1174
        • Muraru D.
        • Badano L.P.
        • Peluso D.
        • Dal Bianco L.
        • Casablanca S.
        • Kocabay G.
        • et al.
        Comprehensive analysis of left ventricular geometry and function by three-dimensional echocardiography in healthy adults.
        J Am Soc Echocardiogr. 2013; 26: 618-628
        • Rietzschel E.R.
        • De Buyzere M.L.
        • Bekaert S.
        • Segers P.
        • De Bacquer D.
        • Cooman L.
        • et al.
        Rationale, design, methods and baseline characteristics of the Asklepios Study.
        Eur J Cardiovasc Prev Rehabil. 2007; 14: 179-191
        • Kuznetsova T.
        • Herbots L.
        • Lopez B.
        • Jin Y.
        • Richart T.
        • Thijs L.
        • et al.
        Prevalence of left ventricular diastolic dysfunction in a general population.
        Circ Heart Fail. 2009; 2: 105-112
        • Friedman G.D.
        • Cutter G.R.
        • Donahue R.P.
        • Hughes G.H.
        • Hulley S.B.
        • Jacobs Jr., D.R.
        • et al.
        CARDIA: study design, recruitment, and some characteristics of the examined subjects.
        J Clin Epidemiol. 1988; 41: 1105-1116
        • Lancellotti P.
        • Badano L.P.
        • Lang R.M.
        • Akhaladze N.
        • Athanassopoulos G.D.
        • Barone D.
        • et al.
        Normal Reference Ranges for Echocardiography: rationale, study design, and methodology (NORRE Study).
        Eur Heart J Cardiovasc Imaging. 2013; 14: 303-308
        • Bountioukos M.
        • Doorduijn J.K.
        • Roelandt J.R.
        • Vourvouri E.C.
        • Bax J.J.
        • Schinkel A.F.
        • et al.
        Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity.
        Eur J Echocardiogr. 2003; 4: 300-305
        • Ryberg M.
        • Nielsen D.
        • Skovsgaard T.
        • Hansen J.
        • Jensen B.V.
        • Dombernowsky P.
        Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
        J Clin Oncol. 1998; 16: 3502-3508
        • Nielsen D.
        • Jensen J.B.
        • Dombernowsky P.
        • Munck O.
        • Fogh J.
        • Brynjolf I.
        • et al.
        Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer.
        J Clin Oncol. 1990; 8: 1806-1810
        • Swain S.M.
        • Whaley F.S.
        • Ewer M.S.
        Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
        Cancer. 2003; 97: 2869-2879
        • Mitani I.
        • Jain D.
        • Joska T.M.
        • Burtness B.
        • Zaret B.L.
        Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.
        J Nucl Cardiol. 2003; 10: 132-139
        • Nousiainen T.
        • Jantunen E.
        • Vanninen E.
        • Hartikainen J.
        Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
        Br J Cancer. 2002; 86: 1697-1700
        • Schwartz R.G.
        • McKenzie W.B.
        • Alexander J.
        • Sager P.
        • D’Souza A.
        • Manatunga A.
        • et al.
        Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
        Am J Med. 1987; 82: 1109-1118
        • Jensen B.V.
        • Skovsgaard T.
        • Nielsen S.L.
        Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.
        Ann Oncol. 2002; 13: 699-709
        • Steinherz L.J.
        • Steinherz P.G.
        • Tan C.T.
        • Heller G.
        • Murphy M.L.
        Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
        JAMA. 1991; 266: 1672-1677
        • Moja L.
        • Tagliabue L.
        • Balduzzi S.
        • Parmelli E.
        • Pistotti V.
        • Guarneri V.
        • et al.
        Trastuzumab containing regimens for early breast cancer.
        Cochrane Database Syst Rev. 2012; 4: CD006243
        • Seidman A.
        • Hudis C.
        • Pierri M.K.
        • Shak S.
        • Paton V.
        • Ashby M.
        • et al.
        Cardiac dysfunction in the trastuzumab clinical trials experience.
        J Clin Oncol. 2002; 20: 1215-1221
        • Youssef G.
        • Links M.
        The prevention and management of cardiovascular complications of chemotherapy in patients with cancer.
        Am J Cardiovasc Drugs. 2005; 5: 233-243
        • Keefe D.L.
        Trastuzumab-associated cardiotoxicity.
        Cancer. 2002; 95: 1592-1600
        • Schuchter L.M.
        • Hensley M.L.
        • Meropol N.J.
        • Winer E.P.
        American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
        J Clin Oncol. 2002; 20: 2895-2903
        • Carver J.R.
        • Shapiro C.L.
        • Ng A.
        • Jacobs L.
        • Schwartz C.
        • Virgo K.S.
        • et al.
        American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
        J Clin Oncol. 2007; 25: 3991-4008
        • Jacobs L.D.
        • Salgo I.S.
        • Goonewardena S.
        • Weinert L.
        • Coon P.
        • Bardo D.
        • et al.
        Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data.
        Eur Heart J. 2006; 27: 460-468
        • Otterstad J.E.
        • Froeland G.
        • St John Sutton M.
        • Holme I.
        Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function.
        Eur Heart J. 1997; 18: 507-513
        • Thavendiranathan P.
        • Grant A.D.
        • Negishi T.
        • Plana J.C.
        • Popovic Z.B.
        • Marwick T.H.
        Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.
        J Am Coll Cardiol. 2013; 61: 77-84
        • Ewer M.S.
        • Ewer S.M.
        Long-term cardiac safety of dose-dense anthracycline therapy cannot be predicted from early ejection fraction data.
        J Clin Oncol. 2009; 27: 6073-6075
        • Karakurt C.
        • Kocak G.
        • Ozgen U.
        Evaluation of the left ventricular function with tissue tracking and tissue Doppler echocardiography in pediatric malignancy survivors after anthracycline therapy.
        Echocardiography. 2008; 25: 880-887
        • Ganame J.
        • Claus P.
        • Eyskens B.
        • Uyttebroeck A.
        • Renard M.
        • D’hooge J.
        • et al.
        Acute cardiac functional and morphological changes after Anthracycline infusions in children.
        Am J Cardiol. 2007; 99: 974-977
        • Tassan-Mangina S.
        • Codorean D.
        • Metivier M.
        • Costa B.
        • Himberlin C.
        • Jouannaud C.
        • et al.
        Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study.
        Eur J Echocardiogr. 2006; 7: 141-146
        • Kapusta L.
        • Thijssen J.M.
        • Groot-Loonen J.
        • Antonius T.
        • Mulder J.
        • Daniels O.
        Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines.
        Ultrasound Med Biol. 2000; 26: 1099-1108
        • Nagueh S.F.
        • Appleton C.P.
        • Gillebert T.C.
        • Marino P.N.
        • Oh J.K.
        • Smiseth O.A.
        • et al.
        Recommendations for the evaluation of left ventricular diastolic function by echocardiography.
        Eur J Echocardiogr. 2009; 10: 165-193
        • Mason J.W.
        • Bristow M.R.
        • Billingham M.E.
        • Daniels J.R.
        Invasive and non invasive methods of assessing Adriamycin cardiotoxic effects in man: superiority of histiopathologic assessment using endomyocardial biopsy.
        Cancer Treat Rep. 1978; 62: 857-864
        • Tanindi A.
        • Demirci U.
        • Tacoy G.
        • Buyukberber S.
        • Alsancak Y.
        • Coskun U.
        • et al.
        Assessment of right ventricular functions during cancer chemotherapy.
        Eur J Echocardiogr. 2011; 12: 834-840
        • Rudski L.G.
        • Lai W.W.
        • Afilalo J.
        • Hua L.
        • Handschumacher M.D.
        • Chandrasekaran K.
        • et al.
        Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.
        J Am Soc Echocardiogr. 2010; 23 (quiz 786–8): 685-713
        • Montani D.
        • Bergot E.
        • Gunther S.
        • Savale L.
        • Bergeron A.
        • Bourdin A.
        • et al.
        Pulmonary arterial hypertension in patients treated by dasatinib.
        Circulation. 2012; 125: 2128-2137
        • Bansal R.C.
        Infective endocarditis.
        Med Clin North Am. 1995; 79: 1205-1240
        • Roberts W.C.
        The congenitally bicuspid aortic valve. A study of 85 autopsy cases.
        Am J Cardiol. 1970; 26: 72-83
        • Freed L.A.
        • Levy D.
        • Levine R.A.
        • Larson M.G.
        • Evans J.C.
        • Fuller D.L.
        • et al.
        Prevalence and clinical outcome of mitral-valve prolapse.
        N Engl J Med. 1999; 341: 1-7
        • Lancellotti P.
        • Nkomo V.T.
        • Badano L.P.
        • Bergler J.
        • Bogaert J.
        • Davin L.
        • et al.
        Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.
        Eur Heart J Cardiovasc Imaging. 2013; 14: 721-740
        • Edoute Y.
        • Haim N.
        • Rinkevich D.
        • Brenner B.
        • Reisner S.A.
        Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients.
        Am J Med. 1997; 102: 252-258
        • Eiken P.W.
        • Edwards W.D.
        • Tazelaar H.D.
        • McBane R.D.
        • Zehr K.J.
        Surgical pathology of nonbacterial thrombotic endocarditis in 30 patients, 1985-2000.
        Mayo Clin Proc. 2001; 76: 1204-1212
        • Hamza A.
        • Tunick P.A.
        • Kronzon I.
        Echocardiographic manifestations of complications of radiation therapy.
        Echocardiography. 2009; 26: 724-728
        • Heidenreich P.A.
        • Kapoor J.R.
        Radiation induced heart disease: systemic disorders in heart disease.
        Heart. 2009; 95: 252-258
        • Heidenreich P.A.
        • Hancock S.L.
        • Lee B.K.
        • Mariscal C.S.
        • Schnittger I.
        Asymptomatic cardiac disease following mediastinal irradiation.
        J Am Coll Cardiol. 2003; 42: 743-749
        • Tomlinson D.
        • Mermel L.A.
        • Ethier M.C.
        • Matlow A.
        • Gillmeister B.
        • Sung L.
        Defining bloodstream infections related to central venous catheters in patients with cancer: a systematic review.
        Clin Infect Dis. 2011; 53: 697-710
        • Baumgartner H.
        • Hung J.
        • Bermejo J.
        • Chambers J.B.
        • Evangelista A.
        • Griffin B.P.
        • et al.
        Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice.
        J Am Soc Echocardiogr. 2009; 22 (quiz 101–2): 1-23
        • Lancellotti P.
        • Tribouilloy C.
        • Hagendorff A.
        • Popescu B.A.
        • Edvardsen T.
        • Pierard L.A.
        • et al.
        Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging.
        Eur Heart J Cardiovasc Imaging. 2013; 14: 611-644
        • Cosyns B.
        • Garbi M.
        • Separovic J.
        • Pasquet A.
        • Lancellotti P.
        Education Committee of the European Association of Cardiovascular Imaging Association (EACVI). Update of the Echocardiography Core Syllabus of the European Association of Cardiovascular Imaging (EACVI).
        Eur Heart J Cardiovasc Imaging. 2013; 14: 837-839
        • Zoghbi W.A.
        • Enriquez-Sarano M.
        • Foster E.
        • Grayburn P.A.
        • Kraft C.D.
        • Levine R.A.
        • et al.
        Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.
        J Am Soc Echocardiogr. 2003; 16: 777-802
        • Mugge A.
        • Daniel W.G.
        • Frank G.
        • Lichtlen P.R.
        Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach.
        J Am Coll Cardiol. 1989; 14: 631-638
        • Klein A.L.
        • Abbara S.
        • Agler D.A.
        • Appleton C.P.
        • Asher C.R.
        • Hoit B.
        • et al.
        American society of echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the society for cardiovascular magnetic resonance and society of cardiovascular computed tomography.
        J Am Soc Echocardiogr. 2013; 26 (e15): 965-1012
        • Bonow R.O.
        • Carabello B.A.
        • Chatterjee K.
        • de Leon Jr., A.C.
        • Faxon D.P.
        • Freed M.D.
        • et al.
        2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
        J Am Coll Cardiol. 2008; 52: e1-e142
        • Vahanian A.
        • Alfieri O.
        • Andreotti F.
        • Antunes M.J.
        • et al.
        • Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC)
        • European Association for Cardio-Thoracic Surgery (EACTS)
        Guidelines on the management of valvular heart disease (version 2012).
        Eur Heart J. 2012; 33: 2451-2496
        • Morton D.L.
        • Glancy D.L.
        • Joseph W.L.
        • Adkins P.C.
        Management of patients with radiation-induced pericarditis with effusion: a note on the development of aortic regurgitation in two of them.
        Chest. 1973; 64: 291-297
        • Gaya A.M.
        • Ashford R.F.
        Cardiac complications of radiation therapy.
        Clin Oncol (R Coll Radiol). 2005; 17: 153-159
        • Krupicka J.
        • Markova J.
        • Pohlreich D.
        • Kozak T.
        • Linkova H.
        • Diehl V.
        • et al.
        Echocardiographic evaluation of acute cardiotoxicity in the treatment of Hodgkin disease according to the German Hodgkin’s Lymphoma Study Group.
        Leuk Lymphoma. 2002; 43: 2325-2329
        • Tohda S.
        • Kobayashi H.
        • Suzuki T.
        • Koyama T.
        • Kamiyama T.
        • Nakamura Y.
        • et al.
        Acute pericarditis caused by daunorubicin in acute myelocytic leukemia.
        Rinsho Ketsueki. 1988; 29: 874-878
        • Casey D.J.
        • Kim A.Y.
        • Olszewski A.J.
        Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma.
        Am J Hematol. 2012; 87: 521-524
        • Dazzi H.
        • Kaufmann K.
        • Follath F.
        Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zurich, Switzerland, between 1990 and 1996.
        Ann Oncol. 2001; 12: 963-966
        • Katayama M.
        • Imai Y.
        • Hashimoto H.
        • Kurata M.
        • Nagai K.
        • Tamita K.
        • et al.
        Fulminant fatal cardiotoxicity following cyclophosphamide therapy.
        J Cardiol. 2009; 54: 330-334
        • Santos G.W.
        • Sensenbrenner L.L.
        • Burke P.J.
        • Colvin M.
        • Owens Jr., A.H.
        • Bias W.B.
        • et al.
        Marrow transplanation in man following cyclophosphamide.
        Transplant Proc. 1971; 3: 400-404
        • Gottdiener J.S.
        • Appelbaum F.R.
        • Ferrans V.J.
        • Deisseroth A.
        • Ziegler J.
        Cardiotoxicity associated with high-dose cyclophosphamide therapy.
        Arch Intern Med. 1981; 141: 758-763
        • Goldberg M.A.
        • Antin J.H.
        • Guinan E.C.
        • Rappeport J.M.
        Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.
        Blood. 1986; 68: 1114-1118
        • Yamamoto R.
        • Kanda Y.
        • Matsuyama T.
        • Oshima K.
        • Nannya Y.
        • Suguro M.
        • et al.
        Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure.
        Bone Marrow Transplant. 2000; 26: 685-688
        • Braverman A.C.
        • Antin J.H.
        • Plappert M.T.
        • Cook E.F.
        • Lee R.T.
        Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.
        J Clin Oncol. 1991; 9: 1215-1223
        • Gahler A.
        • Hitz F.
        • Hess U.
        • Cerny T.
        Acute pericarditis and pleural effusion complicating cytarabine chemotherapy.
        Onkologie. 2003; 26: 348-350
        • Reykdal S.
        • Sham R.
        • Kouides P.
        Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy.
        Leuk Res. 1995; 19: 141-144
        • Yamada T.
        • Tsurumi H.
        • Hara T.
        • Sawada M.
        • Oyama M.
        • Moriwaki H.
        Cytarabine-induced pericarditis.
        Rinsho Ketsueki. 1998; 39: 1115-1120
        • Hermans C.
        • Straetmans N.
        • Michaux J.L.
        • Ferrant A.
        Pericarditis induced by high-dose cytosine arabinoside chemotherapy.
        Ann Hematol. 1997; 75: 55-57
        • Vaickus L.
        • Letendre L.
        Pericarditis induced by high-dose cytarabine therapy.
        Arch Intern Med. 1984; 144: 1868-1869
        • Barton J.C.
        • Jones S.C.
        • Lamberth W.C.
        • Reymann M.T.
        • Scott V.C.
        Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia.
        Am J Hematol. 2002; 71: 139-140
        • Breccia M.
        • D’Elia G.M.
        • D’Andrea M.
        • Latagliata R.
        • Alimena G.
        Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
        Eur J Haematol. 2005; 74: 89-90
        • Breccia M.
        • Alimena G.
        Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
        Expert Opin Drug Saf. 2010; 9: 713-721
        • Krauth M.T.
        • Herndlhofer S.
        • Schmook M.T.
        • Mitterbauer-Hohendanner G.
        • Schlogl E.
        • Valent P.
        Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.
        Haematologica. 2011; 96: 163-166
        • Rauw J.
        • Ahmed S.
        • Petrella T.
        Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma.
        Med Oncol. 2012; 29: 1304-1307
        • Cervera Miguel J.I.
        • Vallalta M.
        • Iranzo E.
        • Navarro Ibanez V.
        Pericardial effusion associated with interferon therapy.
        Med Clin (Barc). 2004; 122: 636-637
        • Velasco J.
        • Orinuela I.
        • Sanjuan A.Z.
        • Ortiz de Zarate Z.
        Pericardial effusion associated to interferon in an immunocompetent patient.
        Enferm Infecc Microbiol Clin. 2010; 28: 749-750
        • Wisniewski B.
        • Denis J.
        • Fischer D.
        • Labayle D.
        Pericarditis secondary to interferon alpha in chronic hepatitis C.
        Gastroenterol Clin Biol. 2004; 28: 315-316
        • Popescu C.
        • Arama V.
        • Gliga S.
        Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis - case report.
        BMC Gastroenterol. 2011; 11 (X-11-30): 30-230
        • Tallman M.S.
        • Andersen J.W.
        • Schiffer C.A.
        • Appelbaum F.R.
        • Feusner J.H.
        • Ogden A.
        • et al.
        All-trans-retinoic acid in acute promyelocytic leukemia.
        N Engl J Med. 1997; 337: 1021-1028
        • Frankel S.R.
        • Eardley A.
        • Lauwers G.
        • Weiss M.
        • Warrell Jr., R.P.
        The “retinoic acid syndrome” in acute promyelocytic leukemia.
        Ann Intern Med. 1992; 117: 292-296
        • Terpstra W.
        • de Maat C.E.
        Pericardial fibrosis following busulfan treatment.
        Neth J Med. 1989; 35: 249-252
        • Forbat L.N.
        • Hancock B.W.
        • Gershlick A.H.
        Methotrexate-induced pericarditis and pericardial effusion; first reported case.
        Postgrad Med J. 1995; 71: 244-245
        • Savoia F.
        • Gaddoni G.
        • Casadio C.
        • Patrizi A.
        • Spadola G.
        • Bassi P.
        • et al.
        A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy.
        Dermatol Online J. 2010; 16: 13
        • Mohyuddin T.
        • Elyan M.
        • Kushner I.
        Pericarditis: a rare complication of methotrexate therapy.
        Clin Rheumatol. 2007; 26: 2157-2158
        • Palungwachira P.
        • Palungwachira P.
        • Laohathai P.
        Methotrexate induced pericarditis and pericardial effusion in psoriatic patient.
        J Med Assoc Thai. 1998; 81: 141-145
        • Huang S.Y.
        • Chang C.S.
        • Tang J.L.
        • Tien H.F.
        • Kuo T.L.
        • Huang S.F.
        • et al.
        Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia.
        Br J Haematol. 1998; 103: 1092-1095
        • Ueda K.
        • Nagai S.
        • Miyashita S.I.
        • Kaise T.
        • Ichikawa M.
        • Kumano K.
        • et al.
        Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
        Leuk Res. 2010; 34: e25-e26
        • Calik A.N.
        • Celiker E.
        • Velibey Y.
        • Cagdas M.
        • Guzelburc O.
        Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis.
        Am J Emerg Med. 2012; 30: 257.e1-257.e3
        • Vincenzi B.
        • Santini D.
        • Frezza A.M.
        • Rocci L.
        • Tonini G.
        Docetaxel induced pericardial effusion.
        J Exp Clin Cancer Res. 2007; 26: 417-420
        • Maisch B.
        • Seferovic P.M.
        • Ristic A.D.
        • Erbel R.
        • Rienmuller R.
        • Adler Y.
        • et al.
        Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology.
        Eur Heart J. 2004; 25: 587-610
        • Appleton C.P.
        • Hatle L.K.
        • Popp R.L.
        Cardiac tamponade and pericardial effusion: respiratory variation in transvalvular flow velocities studied by Doppler echocardiography.
        J Am Coll Cardiol. 1988; 11: 1020-1030
        • Pepi M.
        • Muratori M.
        Echocardiography in the diagnosis and management of pericardial disease.
        J Cardiovasc Med. 2006; 7: 533-544
        • Wann S.
        • Passen E.
        Echocardiography in pericardial disease.
        J Am Soc Echocardiogr. 2008; 21: 7-13
        • Applefeld M.M.
        • Cole J.F.
        • Pollock S.H.
        • Sutton F.J.
        • Slawson R.G.
        • Singleton R.T.
        • et al.
        The late appearance of chronic pericardial disease in patients treated by radiotherapy for Hodgkin’s disease.
        Ann Intern Med. 1981; 94: 338-341
        • Kane G.C.
        • Edie R.N.
        • Mannion J.D.
        Delayed appearance of effusive-constrictive pericarditis after radiation for Hodgkin lymphoma.
        Ann Intern Med. 1996; 124: 534-535
        • Tulleken J.E.
        • Kooiman C.G.
        • van der Werf T.S.
        • Zijlstra J.G.
        • de Vries E.G.
        Constrictive pericarditis after high-dose chemotherapy.
        Lancet. 1997; 350: 1601
        • Oki T.
        • Tabata T.
        • Yamada H.
        • Abe M.
        • Onose Y.
        • Wakatsuki T.
        • et al.
        Right and left ventricular wall motion velocities as diagnostic indicators of constrictive pericarditis.
        Am J Cardiol. 1998; 81: 465-470
        • Sengupta P.P.
        • Mohan J.C.
        • Mehta V.
        • Arora R.
        • Pandian N.G.
        • Khandheria B.K.
        Accuracy and pitfalls of early diastolic motion of the mitral annulus for diagnosing constrictive pericarditis by tissue Doppler imaging.
        Am J Cardiol. 2004; 93: 886-890
        • Sohn D.W.
        • Kim Y.J.
        • Kim H.S.
        • Kim K.B.
        • Park Y.B.
        • Choi Y.S.
        Unique features of early diastolic mitral annulus velocity in constrictive pericarditis.
        J Am Soc Echocardiogr. 2004; 17: 222-226
        • Badano L.P.
        • Boccalini F.
        • Muraru D.
        • Bianco L.D.
        • Peluso D.
        • Bellu R.
        • et al.
        Current clinical applications of transthoracic three-dimensional echocardiography.
        J Cardiovasc Ultrasound. 2012; 20: 1-22
        • Armstrong G.T.
        • Plana J.C.
        • Zhang N.
        • Srivastava D.
        • Green D.M.
        • Ness K.K.
        • et al.
        Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging.
        J Clin Oncol. 2012; 30: 2876-2884
        • Jenkins C.
        • Moir S.
        • Chan J.
        • Rakhit D.
        • Haluska B.
        • Marwick T.H.
        Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging.
        Eur Heart J. 2009; 30: 98-106
        • King D.L.
        • Harrison M.R.
        • King Jr., D.L.
        • Gopal A.S.
        • Kwan O.L.
        • DeMaria A.N.
        Ultrasound beam orientation during standard two-dimensional imaging: assessment by three-dimensional echocardiography.
        J Am Soc Echocardiogr. 1992; 5: 569-576
        • Cannesson M.
        • Tanabe M.
        • Suffoletto M.S.
        • McNamara D.M.
        • Madan S.
        • Lacomis J.M.
        • et al.
        A novel two-dimensional echocardiographic image analysis system using artificial intelligence-learned pattern recognition for rapid automated ejection fraction.
        J Am Coll Cardiol. 2007; 49: 217-226
        • Muraru D.
        • Badano L.P.
        • Piccoli G.
        • Gianfagna P.
        • Del Mestre L.
        • Ermacora D.
        • et al.
        Validation of a novel automated border-detection algorithm for rapid and accurate quantitation of left ventricular volumes based on three-dimensional echocardiography.
        Eur J Echocardiogr. 2010; 11: 359-368
        • Mor-Avi V.
        • Lang R.M.
        Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy?.
        J Am Coll Cardiol. 2013; 61: 85-87
        • Tsang W.
        • Kenny C.
        • Adhya S.
        • Kapetanakis S.
        • Weinert L.
        • Lang R.M.
        • et al.
        Interinstitutional measurements of left ventricular volumes, speckle-tracking strain, and dyssynchrony using three-dimensional echocardiography.
        J Am Soc Echocardiogr. 2013; 26: 1253-1257
        • Yu E.H.
        • Sloggett C.E.
        • Iwanochko R.M.
        • Rakowski H.
        • Siu S.C.
        Feasibility and accuracy of left ventricular volumes and ejection fraction determination by fundamental, tissue harmonic, and intravenous contrast imaging in difficult-to-image patients.
        J Am Soc Echocardiogr. 2000; 13: 216-224
        • Mulvagh S.L.
        • Rakowski H.
        • Vannan M.A.
        • Abdelmoneim S.S.
        • Becher H.
        • Bierig S.M.
        • et al.
        American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography.
        J Am Soc Echocardiogr. 2008; 21 (quiz 1281): 1179-1201
        • Senior R.
        • Becher H.
        • Monaghan M.
        • Agati L.
        • Zamorano J.
        • Vanoverschelde J.L.
        • et al.
        Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography.
        Eur J Echocardiogr. 2009; 10: 194-212
        • Douglas P.S.
        • Carr J.J.
        • Cerqueira M.D.
        • Cummings J.E.
        • Gerber T.C.
        • Mukherjee D.
        • et al.
        Developing an action plan for patient radiation safety in adult cardiovascular medicine: proceedings from the Duke University Clinical Research Institute/American College of Cardiology Foundation/American Heart Association Think Tank held on February 28, 2011.
        J Am Coll Cardiol. 2012; 59: 1833-1847
        • Yeh E.T.H.
        • Bickford C.L.
        Cardiovascular Complications of Cancer Therapy: Incidence, Pathogenesis, Diagnosis, and Management.
        J Am Coll Cardiol. 2009; 53: 2231-2247
        • Jarfelt M.
        • Kujacic V.
        • Holmgren D.
        • Bjarnason R.
        • Lannering B.
        Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia.
        Pediatr Blood Cancer. 2007; 49: 835-840
        • De Wolf D.
        • Suys B.
        • Maurus R.
        • Benoit Y.
        • Verhaaren H.
        • Matthijs D.
        • et al.
        Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors.
        Pediatr Res. 1996; 39: 504-512
        • De Wolf D.
        • Suys B.
        • Verhaaren H.
        • Matthys D.
        • Taeymans Y.
        Low-dose dobutamine stress echocardiography in children and young adults.
        Am J Cardiol. 1998; 81: 895-901
        • Cottin Y.
        • L’huillier I.
        • Casasnovas O.
        • Geoffroy C.
        • Caillot D.
        • Zeller M.
        • et al.
        Dobutamine stress echocardiography identifies anthracycline cardiotoxicity.
        Eur J Echocardiogr. 2000; 1: 180-183
        • Lanzarini L.
        • Bossi G.
        • Laudisa M.L.
        • Klersy C.
        • Arico M.
        Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines.
        Am Heart J. 2000; 140: 315-323
        • Elbl L.
        • Hrstkova H.
        • Chaloupka V.
        • Novotny J.
        • Michalek J.
        The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography.
        Neoplasma. 2003; 50: 191-197
        • Hamada H.
        • Ohkubo T.
        • Maeda M.
        • Ogawa S.
        Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer.
        Pediatr Int. 2006; 48: 313-320
        • Civelli M.
        • Cardinale D.
        • Martinoni A.
        • Lamantia G.
        • Colombo N.
        • Colombo A.
        • et al.
        Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity.
        Int J Cardiol. 2006; 111: 120-126
        • Grosu A.
        • Bombardini T.
        • Senni M.
        • Duino V.
        • Gori M.
        • Picano E.
        End-systolic pressure/volume relationship during dobutamine stress echo: a prognostically useful non-invasive index of left ventricular contractility.
        Eur Heart J. 2005; 26: 2404-2412
        • Tan-Chiu E.
        • Yothers G.
        • Romond E.
        • Geyer Jr., C.E.
        • Ewer M.
        • Keefe D.
        • et al.
        Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
        J Clin Oncol. 2005; 23: 7811-7819
        • Cardinale D.
        • Colombo A.
        • Lamantia G.
        • Colombo N.
        • Civelli M.
        • De Giacomi G.
        • et al.
        Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
        J Am Coll Cardiol. 2010; 55: 213-220
        • Stoddard M.F.
        • Seeger J.
        • Liddell N.E.
        • Hadley T.J.
        • Sullivan D.M.
        • Kupersmith J.
        Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans.
        J Am Coll Cardiol. 1992; 20: 62-69
        • Dorup I.
        • Levitt G.
        • Sullivan I.
        • Sorensen K.
        Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function.
        Heart. 2004; 90: 1214-1216
        • Eidem B.W.
        • Sapp B.G.
        • Suarez C.R.
        • Cetta F.
        Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children.
        Am J Cardiol. 2001; 87 (A9): 1120-1122
        • Ishii M.
        • Tsutsumi T.
        • Himeno W.
        • Eto G.
        • Furui J.
        • Hashino K.
        • et al.
        Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy.
        Am J Cardiol. 2000; 86 (A9): 1279-1281
        • Rohde L.E.
        • Baldi A.
        • Weber C.
        • Geib G.
        • Mazzotti N.G.
        • Fiorentini M.
        • et al.
        Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity.
        Int J Cardiovasc Imaging. 2007; 23: 185-191
        • Pellicori P.
        • Calicchia A.
        • Lococo F.
        • Cimino G.
        • Torromeo C.
        Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol.
        Congest Heart Fail. 2012; 18: 217-221
        • Ho E.
        • Brown A.
        • Barrett P.
        • Morgan R.B.
        • King G.
        • Kennedy M.J.
        • et al.
        Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study.
        Heart. 2010; 96: 701-707
        • Nagy A.C.
        • Tolnay E.
        • Nagykalnai T.
        • Forster T.
        Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI.
        Neoplasma. 2006; 53: 511-517
        • Nagy A.C.
        • Cserep Z.
        • Tolnay E.
        • Nagykalnai T.
        • Forster T.
        Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study.
        Pathol Oncol Res. 2008; 14: 69-77
        • Sawaya H.
        • Sebag I.A.
        • Plana J.C.
        • Januzzi J.L.
        • Ky B.
        • Cohen V.
        • et al.
        Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.
        Am J Cardiol. 2011; 107: 1375-1380
        • Ganame J.
        • Claus P.
        • Uyttebroeck A.
        • Renard M.
        • D’hooge J.
        • Bijnens B.
        • et al.
        Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients.
        J Am Soc Echocardiogr. 2007; 20: 1351-1358
        • Negishi K.
        • Negishi T.
        • Hare J.L.
        • Haluska B.A.
        • Plana J.C.
        • Marwick T.H.
        Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity.
        J Am Soc Echocardiogr. 2013; 26: 493-498
        • Fallah-Rad N.
        • Walker J.R.
        • Wassef A.
        • Lytwyn M.
        • Bohonis S.
        • Fang T.
        • et al.
        The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
        J Am Coll Cardiol. 2011; 57: 2263-2270
        • Thavendiranathan P.
        • Poulin F.
        • Lim K.D.
        • Plana J.C.
        • Woo A.
        • Marwick T.H.
        Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy: A Systematic Review.
        J Am Coll Cardiol. 2014; 63: 2751-2768
        • Jurcut R.
        • Wildiers H.
        • Ganame J.
        • D’hooge J.
        • De Backer J.
        • Denys H.
        • et al.
        Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer.
        J Am Soc Echocardiogr. 2008; 21: 1283-1289
        • Poterucha J.T.
        • Kutty S.
        • Lindquist R.K.
        • Li L.
        • Eidem B.W.
        Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction.
        J Am Soc Echocardiogr. 2012; 25: 733-740
        • Sawaya H.
        • Sebag I.A.
        • Plana J.C.
        • Januzzi J.L.
        • Ky B.
        • Tan T.C.
        • et al.
        Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
        Circ Cardiovasc Imaging. 2012; 5: 596-603
        • Stoodley P.W.
        • Richards D.A.
        • Hui R.
        • Boyd A.
        • Harnett P.R.
        • Meikle S.R.
        • et al.
        Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy.
        Eur J Echocardiogr. 2011; 12: 945-952
        • Hare J.L.
        • Brown J.K.
        • Leano R.
        • Jenkins C.
        • Woodward N.
        • Marwick T.H.
        Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab.
        Am Heart J. 2009; 158: 294-301
        • Cheung Y.F.
        • Hong W.J.
        • Chan G.C.
        • Wong S.J.
        • Ha S.Y.
        Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy.
        Heart. 2010; 96: 1137-1141
        • Tsai H.R.
        • Gjesdal O.
        • Wethal T.
        • Haugaa K.H.
        • Fossa A.
        • Fossa S.D.
        • et al.
        Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin’s lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy.
        Am J Cardiol. 2011; 107: 472-477
        • Kocabay G.
        • Muraru D.
        • Peluso D.
        • Cucchini U.
        • Mihaila S.
        • Padayattil-Jose S.
        • et al.
        Normal left 1 ventricular mechanics by two-dimensional speckle tracking echocardiography. Reference values in healthy adults.
        Rev Esp Cardiol. 2014;
        • Takigiku K.
        • Takeuchi M.
        • Izumi C.
        • Yuda S.
        • Sakata K.
        • Ohte N.
        • et al.
        Normal range of left ventricular 2-dimensional strain: Japanese Ultrasound Speckle Tracking of the Left Ventricle (JUSTICE) study.
        Circ J. 2012; 76: 2623-2632
        • Kuznetsova T.
        • Herbots L.
        • Richart T.
        • D’hooge J.
        • Thijs L.
        • Fagard R.H.
        • et al.
        Left ventricular strain and strain rate in a general population.
        Eur Heart J. 2008; 29: 2014-2023
        • Cheng S.
        • Larson M.G.
        • McCabe E.L.
        • Osypiuk E.
        • Lehman B.T.
        • Stanchev P.
        • et al.
        Reproducibility of Speckle-Tracking-Based Strain Measures of Left Ventricular Function in a Community-Based Study.
        J Am Soc Echocardiogr. 2013; 26: 1258-1266.e2
        • Risum N.
        • Ali S.
        • Olsen N.T.
        • Jons C.
        • Khouri M.G.
        • Lauridsen T.K.
        • et al.
        Variability of global left ventricular deformation analysis using vendor dependent and independent two-dimensional speckle-tracking software in adults.
        J Am Soc Echocardiogr. 2012; 25: 1195-1203
      1. A Unique Collaboration to Advance Strain Imaging.
        Journal of the American Society of Echocardiography. 2013; 26: A21-A22
        • Cardinale D.
        • Sandri M.T.
        Role of biomarkers in chemotherapy-induced cardiotoxicity.
        Prog Cardiovasc Dis. 2010; 53: 121-129
        • Reichlin T.
        • Hochholzer W.
        • Bassetti S.
        • Steuer S.
        • Stelzig C.
        • Hartwiger S.
        • et al.
        Early diagnosis of myocardial infarction with sensitive cardiac troponin assays.
        N Engl J Med. 2009; 361: 858-867
        • Wright R.S.
        • Anderson J.L.
        • Adams C.D.
        • Bridges C.R.
        • Casey Jr., D.E.
        • Ettinger S.M.
        • et al.
        2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons.
        J Am Coll Cardiol. 2011; 57: e215-367
        • Cardinale D.
        • Sandri M.T.
        • Colombo A.
        • Colombo N.
        • Boeri M.
        • Lamantia G.
        • et al.
        Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.
        Circulation. 2004; 109: 2749-2754
        • Auner H.W.
        • Tinchon C.
        • Linkesch W.
        • Tiran A.
        • Quehenberger F.
        • Link H.
        • et al.
        Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies.
        Ann Hematol. 2003; 82: 218-222
        • Specchia G.
        • Buquicchio C.
        • Pansini N.
        • Di Serio F.
        • Liso V.
        • Pastore D.
        • et al.
        Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines.
        J Lab Clin Med. 2005; 145: 212-220
        • Kilickap S.
        • Barista I.
        • Akgul E.
        • Aytemir K.
        • Aksoyek S.
        • Aksoy S.
        • et al.
        cTnT can be a useful marker for early detection of anthracycline cardiotoxicity.
        Ann Oncol. 2005; 16: 798-804
        • Cardinale D.
        • Colombo A.
        • Torrisi R.
        • Sandri M.T.
        • Civelli M.
        • Salvatici M.
        • et al.
        Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
        J Clin Oncol. 2010; 28: 3910-3916
        • Morris P.G.
        • Chen C.
        • Steingart R.
        • Fleisher M.
        • Lin N.
        • Moy B.
        • et al.
        Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
        Clin Cancer Res. 2011; 17: 3490-3499
        • Schmidinger M.
        • Zielinski C.C.
        • Vogl U.M.
        • Bojic A.
        • Bojic M.
        • Schukro C.
        • et al.
        Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2008; 26: 5204-5212
        • Ederhy S.
        • Massard C.
        • Dufaitre G.
        • Balheda R.
        • Meuleman C.
        • Rocca C.G.
        • et al.
        Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials.
        Invest New Drugs. 2012; 30: 611-615
        • Lenihan D.J.
        • Massey M.R.
        • Baysinger K.B.
        • Adorno C.L.
        • Warneke C.L.
        • Steinert D.
        • et al.
        Superior Detection of Cardiotoxicity during Chemotherapy Using Biomarkers.
        J Card Fail. 2007; 13: S151
        • Romano S.
        • Fratini S.
        • Ricevuto E.
        • Procaccini V.
        • Stifano G.
        • Mancini M.
        • et al.
        Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
        Br J Cancer. 2011; 105: 1663-1668
        • Dodos F.
        • Halbsguth T.
        • Erdmann E.
        • Hoppe U.C.
        Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
        Clin Res Cardiol. 2008; 97: 318-326
        • Knobloch K.
        • Tepe J.
        • Lichtinghagen R.
        • Luck H.J.
        • Vogt P.M.
        Monitoring of cardiotoxicity during immunotherapy with Herceptin using simultaneous continuous wave Doppler depending on N-terminal pro-brain natriuretic peptide.
        Clin Med. 2007; 7 (author reply 89): 88-89
        • Knobloch K.
        • Tepe J.
        • Rossner D.
        • Lichtinghagen R.
        • Luck H.J.
        • Busch K.H.
        • et al.
        Combined NT-pro-BNP and CW-Doppler ultrasound cardiac output monitoring (USCOM) in epirubicin and liposomal doxorubicin therapy.
        Int J Cardiol. 2008; 128: 316-325
        • Nousiainen T.
        • Jantunen E.
        • Vanninen E.
        • Remes J.
        • Vuolteenaho O.
        • Hartikainen J.
        Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’s lymphoma.
        Eur J Haematol. 1999; 62: 135-141
      2. Fish M, Lenihan DJ. Effectiveness of using biomarkers to detect and identify cardiotoxicity and describe treatment (PREDICT). 2013;(Accessed 2014 Mar 11) http://clinicaltrials.gov/ct2/show/NCT01311843.

        • Kalam K.
        • Marwick T.H.
        Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis.
        Eur J Cancer. 2013; 49: 2900-2909
        • Lipshultz S.E.
        • Rifai N.
        • Dalton V.M.
        • Levy D.E.
        • Silverman L.B.
        • Lipsitz S.R.
        • et al.
        The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
        N Engl J Med. 2004; 351: 145-153
        • van Dalen E.C.
        • Caron H.N.
        • Dickinson H.O.
        • Kremer L.C.
        Cardioprotective interventions for cancer patients receiving anthracyclines.
        Cochrane Database Syst Rev. 2011; : CD003917
        • Seicean S.
        • Seicean A.
        • Plana J.C.
        • Budd G.T.
        • Marwick T.H.
        Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.
        J Am Coll Cardiol. 2012; 60: 2384-2390
        • Acar Z.
        • Kale A.
        • Turgut M.
        • Demircan S.
        • Durna K.
        • Demir S.
        • et al.
        Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.
        J Am Coll Cardiol. 2011; 58: 988-989
        • Silber J.H.
        • Cnaan A.
        • Clark B.J.
        • Paridon S.M.
        • Chin A.J.
        • Rychik J.
        • et al.
        Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.
        J Clin Oncol. 2004; 22: 820-828
        • Blaes A.H.
        • Gaillard P.
        • Peterson B.A.
        • Yee D.
        • Virnig B.
        Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy.
        Breast Cancer Res Treat. 2010; 122: 585-590
        • Seicean S.
        • Seicean A.
        • Alan N.
        • Plana J.C.
        • Budd G.T.
        • Marwick T.H.
        Cardioprotective Effect of Beta-Adrenoceptor Blockade in Breast Cancer Patients Undergoing Chemotherapy: A Follow-Up Study of Heart Failure.
        Circ Heart Fail. 2013; 6: 420-426
        • Kalay N.
        • Basar E.
        • Ozdogru I.
        • Er O.
        • Cetinkaya Y.
        • Dogan A.
        • et al.
        Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
        J Am Coll Cardiol. 2006; 48: 2258-2262
        • Nakamae H.
        • Tsumura K.
        • Terada Y.
        • Nakane T.
        • Nakamae M.
        • Ohta K.
        • et al.
        Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone.
        Cancer. 2005; 104: 2492-2498
        • Cadeddu C.
        • Piras A.
        • Mantovani G.
        • Deidda M.
        • Dessi M.
        • Madeddu C.
        • et al.
        Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment.
        Am Heart J. 2010; 160: 487.e1-487.e7
        • Negishi T.
        • Negishi K.
        • Agler D.
        • Plana J.C.
        • Haluska B.
        • Marwick T.
        Cardio-protective effect of beta-blockade during chemotherapy for breat cancer.
        J Am Coll Cardiol. 2012; 59: E1248
        • Powe D.G.
        • Entschladen F.
        Targeted therapies: Using beta-blockers to inhibit breast cancer progression.
        Nat Rev Clin Oncol. 2011; 8: 511-512
        • Gottdiener J.S.
        • Mathisen D.J.
        • Borer J.S.
        • Bonow R.O.
        • Myers C.E.
        • Barr L.H.
        • et al.
        Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography.
        Ann Intern Med. 1981; 94: 430-435
        • Choi B.W.
        • Berger H.J.
        • Schwartz P.E.
        • Alexander J.
        • Wackers F.J.
        • Gottschalk A.
        • et al.
        Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.
        Am Heart J. 1983; 106: 638-643
        • Palmeri S.T.
        • Bonow R.O.
        • Myers C.E.
        • Seipp C.
        • Jenkins J.
        • Green M.V.
        • et al.
        Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.
        Am J Cardiol. 1986; 58: 607-613
        • Pinder M.C.
        • Duan Z.
        • Goodwin J.S.
        • Hortobagyi G.N.
        • Giordano S.H.
        Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
        J Clin Oncol. 2007; 25: 3808-3815
        • Bellenger N.G.
        • Burgess M.I.
        • Ray S.G.
        • Lahiri A.
        • Coats A.J.
        • Cleland J.G.
        • et al.
        Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?.
        Eur Heart J. 2000; 21: 1387-1396
        • Naik M.M.
        • Diamond G.A.
        • Pai T.
        • Soffer A.
        • Siegel R.J.
        Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiography.
        J Am Coll Cardiol. 1995; 25: 937-942
        • Mogelvang J.
        • Stokholm K.H.
        • Saunamaki K.
        • Reimer A.
        • Stubgaard M.
        • Thomsen C.
        • et al.
        Assessment of left ventricular volumes by magnetic resonance in comparison with radionuclide angiography, contrast angiography and echocardiography.
        Eur Heart J. 1992; 13: 1677-1683
        • Jiji R.S.
        • Kramer C.M.
        • Salerno M.
        Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.
        J Nucl Cardiol. 2012; 19: 377-388
        • van Royen N.
        • Jaffe C.C.
        • Krumholz H.M.
        • Johnson K.M.
        • Lynch P.J.
        • Natale D.
        • et al.
        Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions.
        Am J Cardiol. 1996; 77: 843-850
        • Abbasi S.A.
        • Ertel A.
        • Shah R.V.
        • Dandekar V.
        • Chung J.
        • Bhat G.
        • et al.
        Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients.
        J Cardiovasc Magn Reson. 2013; 15 (X-15-89): 89-429
        • Greenwood J.P.
        • Maredia N.
        • Younger J.F.
        • Brown J.M.
        • Nixon J.
        • Everett C.C.
        • et al.
        Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial.
        Lancet. 2012; 379: 453-460
        • Klein C.
        • Nekolla S.G.
        • Bengel F.M.
        • Momose M.
        • Sammer A.
        • Haas F.
        • et al.
        Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography.
        Circulation. 2002; 105: 162-167
        • Neilan T.G.
        • Coelho-Filho O.R.
        • Pena-Herrera D.
        • Shah R.V.
        • Jerosch-Herold M.
        • Francis S.A.
        • et al.
        Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.
        Am J Cardiol. 2012; 110: 1679-1686
        • Smith G.
        • Kotwinski P.
        • Carpenter J.P.
        • Hugh M.
        • Pennell D.
        Cardiovascular magnetic resonance imaging in early anthracycline cardiotoxicity.
        J Cardiovasc Magn Reson. 2009; 11: P18
        • Pennell D.J.
        • Sechtem U.P.
        • Higgins C.B.
        • Manning W.J.
        • Pohost G.M.
        • Rademakers F.E.
        • et al.
        Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report.
        J Cardiovasc Magn Reson. 2004; 6: 727-765
        • Kawel N.
        • Turkbey E.B.
        • Carr J.J.
        • Eng J.
        • Gomes A.S.
        • Hundley W.G.
        • et al.
        Normal left ventricular myocardial thickness for middle-aged and older subjects with steady-state free precession cardiac magnetic resonance: the multi-ethnic study of atherosclerosis.
        Circ Cardiovasc Imaging. 2012; 5: 500-508
      3. The clinical role of magnetic resonance in cardiovascular disease. Task Force of the European Society of Cardiology, in collaboration with the Association of European Paediatric Cardiologists.
        Eur Heart J. 1998; 19: 19-39
        • Bellenger N.G.
        • Davies L.C.
        • Francis J.M.
        • Coats A.J.
        • Pennell D.J.
        Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance.
        J Cardiovasc Magn Reson. 2000; 2: 271-278
        • Grothues F.
        • Smith G.C.
        • Moon J.C.
        • Bellenger N.G.
        • Collins P.
        • Klein H.U.
        • et al.
        Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy.
        Am J Cardiol. 2002; 90: 29-34
        • Armstrong A.C.
        • Gidding S.
        • Gjesdal O.
        • Wu C.
        • Bluemke D.A.
        • Lima J.A.
        LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice.
        JACC Cardiovasc Imaging. 2012; 5: 837-848
        • Vogel-Claussen J.
        • Finn J.P.
        • Gomes A.S.
        • Hundley G.W.
        • Jerosch-Herold M.
        • Pearson G.
        • et al.
        Left ventricular papillary muscle mass: relationship to left ventricular mass and volumes by magnetic resonance imaging.
        J Comput Assist Tomogr. 2006; 30: 426-432
        • Alfakih K.
        • Bloomer T.
        • Bainbridge S.
        • Bainbridge G.
        • Ridgway J.
        • Williams G.
        • et al.
        A comparison of left ventricular mass between two-dimensional echocardiography, using fundamental and tissue harmonic imaging, and cardiac MRI in patients with hypertension.
        Eur J Radiol. 2004; 52: 103-109
        • Missouris C.G.
        • Forbat S.M.
        • Singer D.R.
        • Markandu N.D.
        • Underwood R.
        • MacGregor G.A.
        Echocardiography overestimates left ventricular mass: a comparative study with magnetic resonance imaging in patients with hypertension.
        J Hypertens. 1996; 14: 1005-1010
        • Goldman M.
        • Matthews R.
        • Meng H.
        • Bilfinger T.
        • Kort S.
        Evaluation of cardiac involvement with mediastinal lymphoma: the role of innovative integrated cardiovascular imaging.
        Echocardiography. 2012; 29: E189-E192
        • Kim R.J.
        • Wu E.
        • Rafael A.
        • Chen E.L.
        • Parker M.A.
        • Simonetti O.
        • et al.
        The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.
        N Engl J Med. 2000; 343: 1445-1453
        • Perez-Rodriguez J.
        • Lai S.
        • Ehst B.D.
        • Fine D.M.
        • Bluemke D.A.
        Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment–report of 33 cases.
        Radiology. 2009; 250: 371-377
        • Iles L.
        • Pfluger H.
        • Phrommintikul A.
        • Cherayath J.
        • Aksit P.
        • Gupta S.N.
        • et al.
        Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping.
        J Am Coll Cardiol. 2008; 52: 1574-1580
        • Ugander M.
        • Oki A.J.
        • Hsu L.Y.
        • Kellman P.
        • Greiser A.
        • Aletras A.H.
        • et al.
        Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology.
        Eur Heart J. 2012; 33: 1268-1278
        • Tham E.
        • Chow K.
        • Spavor M.
        • Pagano J.J.
        • Haykowsky M.
        • Thompson R.J.
        Degree of diffuse fibrosis measured by MRI correlates with LV remodelling in childhood cancer survivors after anthracycline chemotherapy.
        J Cardiovasc Magn Reson. 2011; 13: P276
        • Neilan T.G.
        • Coelho-Filho O.R.
        • Shah R.V.
        • Feng J.H.
        • Pena-Herrera D.
        • Mandry D.
        • et al.
        Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy.
        Am J Cardiol. 2013; 111: 717-722
        • Korinek J.
        • Kjaergaard J.
        • Sengupta P.P.
        • Yoshifuku S.
        • McMahon E.M.
        • Cha S.S.
        • et al.
        High spatial resolution speckle tracking improves accuracy of 2-dimensional strain measurements: an update on a new method in functional echocardiography.
        J Am Soc Echocardiogr. 2007; 20: 165-170
        • Drafts B.C.
        • Twomley K.M.
        • D’Agostino Jr., R.
        • Lawrence J.
        • Avis N.
        • Ellis L.R.
        • et al.
        Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
        JACC Cardiovasc Imaging. 2013; 6: 877-885
        • Mornos C.
        • Petrescu L.
        Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist.
        Can J Physiol Pharmacol. 2013; 91: 601-607
        • Baratta S.
        • Damiano M.
        • Marchese M.
        • Trucco J.
        • Rizzo M.
        • Bernok F.
        • et al.
        Serum Markers, Conventional Doppler Echocardiography and Two-dimensional Systolic Strain in the Diagnosis of Chemotherapy-Induced Myocardial Toxicity.
        Rev Argent Cardiol. 2013; 81: 151-158
        • Mavinkurve-Groothuis A.M.
        • Marcus K.A.
        • Pourier M.
        • Loonen J.
        • Feuth T.
        • Hoogerbrugge P.M.
        • et al.
        Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
        Eur Heart J Cardiovasc Imaging. 2013; 14: 562-569
        • Stanton T.
        • Leano R.
        • Marwick T.H.
        Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring.
        Circ Cardiovasc Imaging. 2009; 2: 356-364
        • Cho G.Y.
        • Marwick T.H.
        • Kim H.S.
        • Kim M.K.
        • Hong K.S.
        • Oh D.J.
        Global 2-dimensional strain as a new prognosticator in patients with heart failure.
        J Am Coll Cardiol. 2009; 54: 618-624